Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02814318 · ClinicalTrials.gov registry record
Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
A clinical trial, sponsored by TriHealth.
- Terminated
- Registry status
- 41
- Enrollment target
NCT02814318 is a clinical trial that was terminated before completion, run by TriHealth. The registered enrollment target is 41 participants.
The verdict
NCT02814318 was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- 41 participants
- Enrollment target
Study Summary
The aim of this project is to identify the duration of vancomycin administration at which group B streptococcus (GBS) colonization is eradicated from the vaginal and recto-vaginal mucosa. This will aid in labor management and delivery planning to ensure that the mother receives adequate GBS prophylaxis while also minimizing the duration of exposure to vancomycin. In addition, this could prevent unnecessary prolonged hospitalization or septic workup of neonates whose mothers received vancomycin intrapartum. This study aims to identify the time after administration of IV vancomycin at which GBS colonies are 100% eradicated.
Interventions
- BIOLOGICAL Vaginal and rectovaginal swab cultures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02814318
The ClinicalTrials.gov registry entry for NCT02814318 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vaginal and rectovaginal swab cultures is the first listed.
NCT02814318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02814318 about?
NCT02814318 is a clinical study titled "Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization". The aim of this project is to identify the duration of vancomycin administration at which group B streptococcus (GBS) colonization is eradicated from the vaginal and recto-vaginal mucosa. This will aid in labor management and delivery planning to ensure that the mother receives adequate GBS prophyla...
What is the current status of trial NCT02814318?
This trial is currently terminated. The enrollment target is 41 participants. The study started on 2016-06. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02814318?
The interventions under investigation include: Vaginal and rectovaginal swab cultures (BIOLOGICAL).
Who is sponsoring clinical trial NCT02814318?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.